Literature DB >> 7681507

Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart.

Y Nishinaka1, S Sugiyama, M Yokota, H Saito, T Ozawa.   

Abstract

We investigated the cardioprotective effect of FK506, a newly developed immunosuppressive agent, on ischemia-reperfusion-induced myocardial damage and the inhibitory effect of FK506 on superoxide radical formation by neutrophils. Open-chest anesthetized dogs were divided into two groups: group 1, 2-h occlusion of the coronary artery followed by 1-h reperfusion; and group 2, 2-h occlusion followed by 1-h reperfusion with preadministration of FK506 (0.5 mg/kg). After reperfusion, heart mitochondria were prepared from the normal and reperfused areas and mitochondrial function and mitochondrial GSH (the reduced form of glutathione) and GSSG (the oxidized form of glutathione) concentrations were measured. In addition, neutrophils were collected from normal healthy dogs, and the inhibitory effect of FK506 on superoxide radical formation by neutrophils was also investigated. One-hour reperfusion after 2-h coronary occlusion induced significant mitochondrial dysfunction associated with a marked depletion of mitochondrial GSH concentration. FK506 reduced mitochondrial dysfunction, depletion of mitochondrial GSH concentration, and development of reperfusion arrhythmias. FK506 also reduced stimulant-induced superoxide radical formation by normal neutrophils dose dependently. Radical scavenging activity decreased in association with reperfusion, and FK506 reduced superoxide radical formation by neutrophils, which might contribute to lessening ischemia-reperfusion damage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681507     DOI: 10.1097/00005344-199303000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

1.  Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism.

Authors:  S P Butcher; D C Henshall; Y Teramura; K Iwasaki; J Sharkey
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

2.  Pharmacological preconditioning of primary rat cardiac myocytes by FK506.

Authors:  D V Cumming; R J Heads; R S Coffin; D M Yellon; D S Latchman
Journal:  Basic Res Cardiol       Date:  1996 Sep-Oct       Impact factor: 17.165

3.  Post-ischemic alterations in [3H]FK506 binding in the gerbil and rat brains.

Authors:  T Araki; H Kato; K Shuto; Y Itoyama
Journal:  Metab Brain Dis       Date:  1998-03       Impact factor: 3.584

4.  Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation.

Authors:  T Araki; H Tanji; K Fujihara; H Kato; Y Itoyama
Journal:  Metab Brain Dis       Date:  1999-03       Impact factor: 3.584

5.  Effect of ONO-4057 and tacrolimus on ischemia-reperfusion injury of the liver.

Authors:  Takayuki Takeichi; Shinji Uemoto; Sachiko Minamiguchi; Izumi Takeyoshi; Yukihiro Inomata; Koichi Tanaka; Eiji Kobayashi
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

Review 6.  Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart.

Authors:  Yan Burelle; Maya Khairallah; Alexis Ascah; Bruce G Allen; Christian F Deschepper; Basil J Petrof; Christine Des Rosiers
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

7.  Neuroprotective effects of Tacrolimus (FK-506) and Cyclosporin (CsA) in oxidative injury.

Authors:  Seema Yousuf; Fahim Atif; Varun Kesherwani; Sandeep Kumar Agrawal
Journal:  Brain Behav       Date:  2011-11       Impact factor: 2.708

Review 8.  Cardiovascular effects of immunosuppression agents.

Authors:  Aly Elezaby; Ryan Dexheimer; Karim Sallam
Journal:  Front Cardiovasc Med       Date:  2022-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.